Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Biorasis
company
About
Biorasis commercializes wireless, needle implantable, miniaturized sensor platforms for real-time glucose monitoring.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $696.40K
- Industries
- Biotechnology,Health Care,Internet,Wireless
- Founded date
- Dec 1, 2007
- Number Of Employee
- 11 - 50
- Operating Status
- Active
BIORASIS was established in Dec. 2007 with an initial goal to commercialize UCONN’s and OSCI’s wireless, needle-implantable, miniaturized (0.5 x 0.5 x 5 mm) sensor platform for real time, continuous glucose monitoring.
In addition to glucose monitoring Biorasis is working towards outfitting its sensor platform to monitor other bio-analytes in the body that are important in other disorders such as cardiovascular, cancer, liver, kidney abnormalities, stroke and epilepsy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$696.40K
Biorasis has raised a total of
$696.40K
in funding over 2 rounds. Their latest funding was raised on
Aug 27, 2012 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 27, 2012 | Grant | $696.40K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Biorasis is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
